

M Elaine Husni

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3918965/publications.pdf>

Version: 2024-02-01

61
papers

4,169
citations

257450

24
h-index

182427

51
g-index

62
all docs

62
docs citations

62
times ranked

4585
citing authors

#	ARTICLE	IF	CITATIONS
1	Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2016, 68, 1060-1071.	5.6	726
2	Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. <i>New England Journal of Medicine</i> , 2016, 375, 2519-2529.	27.0	607
3	2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2019, 71, 5-32.	5.6	312
4	2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. <i>Arthritis Care and Research</i> , 2019, 71, 2-29.	3.4	264
5	Knee Osteoarthritis: A Primer. , 2017, 21, 16-183.		238
6	The PASE questionnaire: Pilot-testing a Psoriatic Arthritis Screening and Evaluation tool. <i>Journal of the American Academy of Dermatology</i> , 2007, 57, 581-587.	1.2	187
7	Etanercept in the treatment of adult patients with Still's disease. <i>Arthritis and Rheumatism</i> , 2002, 46, 1171-1176.	6.7	179
8	Oral or transdermal opioids for osteoarthritis of the knee or hip. <i>The Cochrane Library</i> , 2014, 2014, CD003115.	2.8	153
9	Recognizing and managing comorbidities in psoriatic arthritis. <i>Current Opinion in Rheumatology</i> , 2015, 27, 118-126.	4.3	146
10	The psychosocial burden of psoriatic arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 47, 351-360.	3.4	124
11	Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis. <i>American Heart Journal</i> , 2009, 157, 606-612.	2.7	115
12	Hip Osteoarthritis: A Primer. , 2018, 22, 17-084.		113
13	Comorbidities in Psoriatic Arthritis. <i>Rheumatic Disease Clinics of North America</i> , 2015, 41, 677-698.	1.9	107
14	Safety and Efficacy of Intravenous Golimumab in Patients With Active Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2017, 69, 2151-2161.	5.6	90
15	Validity, reliability, and sensitivity-to-change properties of the psoriatic arthritis screening and evaluation questionnaire. <i>Archives of Dermatological Research</i> , 2009, 301, 573-579.	1.9	89
16	Comprehensive Treatment of Psoriatic Arthritis: Managing Comorbidities and Extraarticular Manifestations. <i>Journal of Rheumatology</i> , 2014, 41, 2315-2322.	2.0	66
17	Comparing patient-perceived and physician-perceived remission and low disease activity in psoriatic arthritis: an analysis of 410 patients from 14 countries. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 201-208.	0.9	59
18	Relationship Between Metabolic Syndrome and Carotid Intima-Media Thickness: Cross-Sectional Comparison Between Psoriasis and Psoriatic Arthritis. <i>Arthritis Care and Research</i> , 2014, 66, 97-103.	3.4	44

#	ARTICLE	IF	CITATIONS
19	Elevated levels of plasma symmetric dimethylarginine and increased arginase activity as potential indicators of cardiovascular comorbidity in rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2018, 20, 123.	3.5	42
20	Determinants of Patient-Reported Psoriatic Arthritis Impact of Disease: An Analysis of the Association With Sex in 458 Patients From Fourteen Countries. <i>Arthritis Care and Research</i> , 2020, 72, 1772-1779.	3.4	39
21	Development of Screening Tools to Identify Psoriatic Arthritis. <i>Current Rheumatology Reports</i> , 2010, 12, 295-299.	4.7	34
22	KLK6 expression in skin induces PAR1-mediated psoriasiform dermatitis and inflammatory joint disease. <i>Journal of Clinical Investigation</i> , 2020, 130, 3151-3157.	8.2	34
23	Differences in Safety of Nonsteroidal Antiinflammatory Drugs in Patients With Osteoarthritis and Patients With Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2018, 70, 537-546.	5.6	33
24	Cardiometabolic profile, clinical features, quality of life and treatment outcomes in patients with moderate-to-severe psoriasis and psoriatic arthritis. <i>Journal of Dermatological Treatment</i> , 2015, 26, 7-15.	2.2	32
25	Managing Comorbid Disease in Patients with Psoriatic Arthritis. <i>Current Rheumatology Reports</i> , 2010, 12, 281-287.	4.7	31
26	Psoriatic arthritis and psoriasis: Need for a multidisciplinary approach. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2005, 24, 46-51.	1.6	26
27	Decreasing medical complications for total knee arthroplasty: Effect of Critical Pathways on Outcomes. <i>BMC Musculoskeletal Disorders</i> , 2010, 11, 160.	1.9	23
28	Psoriasis and Cardiovascular Disease: Novel Mechanisms and Evolving Therapeutics. <i>Current Atherosclerosis Reports</i> , 2021, 23, 67.	4.8	23
29	Correlation of High-Density Lipoprotein-Associated Paraoxonase 1 Activity With Systemic Inflammation, Disease Activity, and Cardiovascular Risk Factors in Psoriatic Disease. <i>Arthritis and Rheumatology</i> , 2018, 70, 1240-1250.	5.6	19
30	Validation in Spanish of a screening questionnaire for the detection of psoriatic arthritis in patients with psoriasis. <i>Rheumatology</i> , 2013, 52, 510-514.	1.9	18
31	Bone Marrow Cellular Therapies: Novel Therapy for Knee Osteoarthritis. <i>Journal of Knee Surgery</i> , 2018, 31, 022-026.	1.6	16
32	Comparison of US patient, rheumatologist, and dermatologist perceptions of psoriatic disease symptoms: results from the DISCONNECT study. <i>Arthritis Research and Therapy</i> , 2018, 20, 102.	3.5	15
33	Efficacy and Safety of Intravenous Golimumab Through One Year in Patients With Active Psoriatic Arthritis. <i>Arthritis Care and Research</i> , 2020, 72, 806-813.	3.4	14
34	Measuring Outcomes in Psoriatic Arthritis: Comparing Routine Assessment of Patient Index Data and Psoriatic Arthritis Impact of Disease. <i>Journal of Rheumatology</i> , 2020, 47, 1496-1505.	2.0	14
35	Quantifying harmful effects of psoriatic diseases on quality of life: Cardio-metabolic outcomes in psoriatic arthritis study (COMPASS). <i>Seminars in Arthritis and Rheumatism</i> , 2015, 44, 641-645.	3.4	13
36	HDL function and subclinical atherosclerosis in juvenile idiopathic arthritis. <i>Cardiovascular Diagnosis and Therapy</i> , 2016, 6, 34-43.	1.7	13

#	ARTICLE	IF	CITATIONS
37	The impact of identifying carotid plaque on addressing cardiovascular risk in psoriatic arthritis. <i>Arthritis Research and Therapy</i> , 2016, 18, 178.	3.5	12
38	Effect of Secukinumab on the Different GRAPPA-OMERACT Core Domains in Psoriatic Arthritis: A Pooled Analysis of 2049 Patients. <i>Journal of Rheumatology</i> , 2020, 47, 854-864.	2.0	10
39	<p>Treatment Mode Preferences in Psoriatic Arthritis: A Qualitative Multi-Country Study</p>. <i>Patient Preference and Adherence</i> , 2020, Volume 14, 949-961.	1.8	10
40	Utility of the PASE questionnaire, psoriatic arthritis (PsA) prevalence and PsA improvement with anti-TNF therapy: results from the PRISTINE trial. <i>Journal of Dermatological Treatment</i> , 2014, 25, 90-95.	2.2	9
41	Comprehensive Assessment of the Psoriasis Patient (CAPP): A Report from the GRAPPA 2015 Annual Meeting. <i>Journal of Rheumatology</i> , 2016, 43, 961-964.	2.0	9
42	A comparison of physical function instruments in psoriatic arthritis: HAQ-DI <i>vs</i> MDHAQ <i>vs</i> PROMIS10 global physical health. <i>Rheumatology</i> , 2021, 60, 2307-2316.	1.9	9
43	Evaluation of Improvement in Skin and Nail Psoriasis in Bio“na”ve Patients With Active Psoriatic Arthritis Treated With Golumumab: Results Through Week 52 of the GO“VIBRANT Study. <i>ACR Open Rheumatology</i> , 2020, 2, 640-647.	2.1	8
44	Radiographic Progression Inhibition with Intravenous Golumumab in Psoriatic Arthritis: Week 24 Results of a Phase III, Randomized, Double-blind, Placebo-controlled Trial. <i>Journal of Rheumatology</i> , 2019, 46, 595-602.	2.0	6
45	The impact of functional medicine on patient-reported outcomes in inflammatory arthritis: A retrospective study. <i>PLoS ONE</i> , 2020, 15, e0240416.	2.5	6
46	Screening Instruments for Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2013, 40, 1623-1623.	2.0	5
47	TNFR2 Depletion Reduces Psoriatic Inflammation in Mice by Downregulating Specific Dendritic Cell Populations in Lymph Nodes and Inhibiting IL-23/IL-17 Pathways. <i>Journal of Investigative Dermatology</i> , 2022, 142, 2159-2172.e9.	0.7	4
48	Pooled safety results across phase 3 randomized trials of intravenous golumumab in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. <i>Arthritis Research and Therapy</i> , 2022, 24, 73.	3.5	4
49	Disparities in healthcare in psoriatic arthritis: an analysis of 439 patients from 13 countries. <i>RMD Open</i> , 2022, 8, e002031.	3.8	4
50	The potential benefits of aspirin for primary cardiovascular prevention in rheumatoid arthritis: a secondary analysis of the PRECISION Trial. <i>Rheumatology</i> , 2018, 57, 1364-1369.	1.9	3
51	Effects of Intravenous Golumumab on Health-Related Quality of Life in Patients With Psoriatic Arthritis: 24-Week Results of the GO-VIBRANT Trial. <i>Value in Health</i> , 2020, 23, 1286-1291.	0.3	3
52	The effect of intravenous golumumab on health-related quality of life and work productivity in patients with active psoriatic arthritis: results of the Phase 3 GO-VIBRANT trial. <i>Clinical Rheumatology</i> , 2021, 40, 3667-3677.	2.2	3
53	Biologic initiation rates in systemic-naive psoriasis patients after first-line apremilast versus methotrexate use. <i>Journal of Comparative Effectiveness Research</i> , 2022, 11, 575-582.	1.4	1
54	Heart Failure and Inflammatory Arthritis: the Relationship of Systemic Inflammation. <i>Current Cardiovascular Risk Reports</i> , 2016, 10, 1.	2.0	0

#	ARTICLE	IF	CITATIONS
55	Classification and epidemiology of psoriatic arthritis. , 2015, , 986-988.		0
56	2021 GRAPPA Trainee Symposium: A Summary of Oral and Poster Presentations. Journal of Rheumatology, 2022, , jrheum.211318.	2.0	0
57	Title is missing!. , 2020, 15, e0240416.		0
58	Title is missing!. , 2020, 15, e0240416.		0
59	Title is missing!. , 2020, 15, e0240416.		0
60	Title is missing!. , 2020, 15, e0240416.		0
61	Biologic Initiation Rate in Systemic-NA ⁺ ve Psoriatic Arthritis Patients Starting Treatment with Apremilast vs Methotrexate: 1-Year Retrospective Analysis of a US Claims Database. Open Access Rheumatology: Research and Reviews, 0, Volume 14, 123-132.	1.6	0